




RealRate

PHARMACEUTICAL 2026

Verrica Pharmaceuticals Inc
Rank 88 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Verrica Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verrica Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Verrica Pharmaceuticals Inc is the variable Assets, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 3.8% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	42,539
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,437
Liabilities, Non-Current	242
Other Assets	4,383
Other Compr. Net Income	0
Other Expenses	3,687
Other Liabilities	5,709
Other Net Income	-5,701
Other Revenues	35,577
Property and Equipment	209
Research and Development	8,855
Selling, General and Administrative Expense	35,220

Output Variable	Value in 1000 USD
Assets	47,131
Liabilities	22,388
Expenses	47,762
Revenues	35,577
Stockholders Equity	24,743
Net Income	-17,886
Comprehensive Net Income	-17,886
BaseVar	79,280
ECR before Limited Liability	104%
Economic Capital Ratio	233%